Point-of-care G6PD diagnostics for Plasmodium vivax malaria is a clinical and public health urgency

BMC Medicine

Volumn 13, Issue 1, 2015, Pages

  Baird, J Kevin ^a,b  

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Acute hemolytic anemia; Diagnostics; G6PD deficiency; Hypnozoite; Plasmodium vivax; Primaquine therapy; Relapse

Indexed keywords

PRIMAQUINE; ANTIMALARIAL AGENT; GLUCOSE 6 PHOSPHATE DEHYDROGENASE;

DIAGNOSTIC KIT; DISEASE COURSE; ENDEMIC DISEASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOLYTIC ANEMIA; HUMAN; INCIDENCE; MORTALITY; NOTE; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; POINT OF CARE TESTING; PREVALENCE; PUBLIC HEALTH; RISK BENEFIT ANALYSIS; RURAL POPULATION; COMPLICATION; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; MALARIA, VIVAX; POINT OF CARE SYSTEM; PROCEDURES;

ANTIMALARIALS; GLUCOSEPHOSPHATE DEHYDROGENASE; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HUMANS; MALARIA, VIVAX; POINT-OF-CARE SYSTEMS; PRIMAQUINE; PUBLIC HEALTH;

EID: 84952872866     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-015-0531-0     Document Type: Note

References (25)

1. Baird JK. Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria. Pathog Glob Health. 2015;109:93-106.
2. Satyagraha AW, Sadhewa A, Baramuli V, Elvira R, Ridenour C, Elyazar I, et al. G6PD deficiency at Sumba in eastern Indonesia is prevalent, diverse, and severe: implications for primaquine therapy against relapsing vivax malaria. PLoS Negl Trop Dis. 2015;9:e0003602.
3. Howes RE, Piel FB, Patil AP, Gething PW, Dewi M, Hogg MM, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9:e1001339.
4. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. Am J Trop Med Hyg. 2007;77(6 Suppl):79-87.
5. Baird JK. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev. 2013;26:36-57.
6. Bruce-Chwatt LJ, Black RH, Canfield CJ, Clyde DF, Peters W, Wernsdorfer WH. Chemotherapy of malaria. 2nd ed. Geneva: World Health Organization; 1981.
7. Recht J, Ashley E, White N. Safety of 8-aminoquinoline antimalarial medicines. Geneva: World Health Organization; 2014.
8. World Health Organization. Global technical strategy for malaria 2016-2030. Geneva: World Health Organization; 2015.
9. World Health Organization. Control and elimination of Plasmodium vivax malaria. A technical brief. Geneva: World Health Organization; 2015.
10. World Health Organization. Point-of-care G6PD testing to support safe use of primaquine for the treatment of vivax malaria. WHO Evidence Review Group meeting report, 8-9 October 2014, WHO/UNAIDS Building, Geneva, Switzerland. Geneva: World Health Organization; 2015.
11. Battle KE, Karhunen MS, Bhatt S, Gething PW, Howes RE, Golding N, et al. Geographical variation in Plasmodium vivax relapse. Malaria J. 2014;13:144.
12. Hill E, Amatuzio DS. Southwest Pacific vivax malaria: clinical features and observations concerning duration of clinical activity. Am J Trop Med Hyg. 1949;29:203-14.
13. Sutanto I, Tjahjono B, Basri H, Taylor WR, Putri FA, Meilia RA, et al. Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrob Agents Chemother. 2013;57:1128-35.
14. White MT, Karl S, Battle KE, Hay SI, Mueller I, Ghani AC. Modelling the contribution of the hypnozoite reservoir to Plasmodium vivax transmission. Elife. 2014; 3. doi: 10.7554/eLife.04692
15. Roy M, Bouma MJ, Ionides EL, Dhiman RC, Pascual M. The potential elimination of Plasmodium vivax malaria by relapse treatment: insights from a transmission model and surveillance data from NW India. PLoS Negl Trop Dis. 2013;7:e1979.
16. Maude RJ, Nguon C, Ly P, Bunkea T, Ngor P, de la Torre SE C, et al. Spatial and temporal epidemiology of clinical malaria in Cambodia 2004-2013. Malaria J. 2014;13:385.
17. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014;383:1049-58.
18. Domingo GJ, Satyagraha AW, Anvikar A, Baird JK, Bancone G, Bansil P, et al. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Malaria J. 2013;12:391.
19. Osorio L, Carter N, Arthur P, Bancone G, Gopalan S, Gupta SK, et al. Performance of BinaxNOW G6PD deficiency point-of-care diagnostic in P. vivax-infected subjects. Am J Trop Med Hyg. 2015;92:22-7.
20. Tinley KE, Loughlin AM, Jepson A, Barnett ED. Evaluation of a rapid qualitative enzyme chromatographic test for glucose-6-phosphate dehydrogenase deficiency. Am J Trop Med Hyg. 2010;82:210-4.
21. LaRue N, Kahn M, Murray M, Leader BT, Bansil P, McGray S, et al. Comparison of quantitative and qualitative tests for glucose-6-phosphate dehydrogenase deficiency. Am J Trop Med Hyg. 2014;91:854-61.
22. Baird JK, Dewi M, Subekti D, Elyazar I, Satyagraha AW. Non-inferiority of glucose-6-phosphate dehydrogenase deficiency diagnosis by a point-of-care rapid test vs the laboratory fluorescent spot test demonstrated by copper inhibition in normal human red blood cells. Transl Res. 2015;165:677-88.
23. Adu-Gyasi D, Asante KP, Newton S, Dosoo D, Amoako S, Adjei G, et al. Evaluation of the diagnostic accuracy of CareStart G6PD deficiency Rapid Diagnostic Test (RDT) in a malaria endemic area in Ghana, Africa. PLoS One. 2015;10:e0125796.
24. von Fricken ME, Weppelmann TA, Eaton WT, Masse R, de Rochars MV B, Okech BA. Performance of the CareStart glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test in Gressier, Haiti. Am J Trop Med Hyg. 2014;91:77-80.
25. Roca-Feltrer A, Khim N, Kim S, Chy S, Canier L, Kerleguer A, et al. Field trial evaluation of the performances of point-of-care tests for screening G6PD deficiency in Cambodia. PLoS One. 2014;9:e116143.